178 related articles for article (PubMed ID: 16377383)
1. Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin.
Borawski J
Am J Kidney Dis; 2006 Jan; 47(1):37-41. PubMed ID: 16377383
[TBL] [Abstract][Full Text] [Related]
2. Acute effect of standard heparin versus low molecular weight heparin on oxidative stress and inflammation in hemodialysis patients.
Poyrazoglu OK; Dogukan A; Yalniz M; Seckin D; Gunal AL
Ren Fail; 2006; 28(8):723-7. PubMed ID: 17162433
[TBL] [Abstract][Full Text] [Related]
3. Review: anticoagulation for haemodialysis.
Suranyi M; Chow JS
Nephrology (Carlton); 2010 Jun; 15(4):386-92. PubMed ID: 20609088
[TBL] [Abstract][Full Text] [Related]
4. Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes.
Wu CC; Chen JS; Wu WM; Liao TN; Chu P; Lin SH; Chuang CH; Lin YF
Nephrol Dial Transplant; 2005 Jun; 20(6):1134-9. PubMed ID: 15814542
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of myeloperoxidase and elastase are differentially regulated by hemodialysis membranes and anticoagulants.
Ono K; Ueki K; Inose K; Tsuchida A; Yano S; Nojima Y
Res Commun Mol Pathol Pharmacol; 2000; 108(5-6):341-9. PubMed ID: 11958287
[TBL] [Abstract][Full Text] [Related]
6. Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis.
Gritters M; Grooteman MP; Schoorl M; Schoorl M; Bartels PC; Scheffer PG; Teerlink T; Schalkwijk CG; Spreeuwenberg M; Nubé MJ
Nephrol Dial Transplant; 2006 Jan; 21(1):153-9. PubMed ID: 16144857
[TBL] [Abstract][Full Text] [Related]
7. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase.
Baldus S; Rudolph V; Roiss M; Ito WD; Rudolph TK; Eiserich JP; Sydow K; Lau D; Szöcs K; Klinke A; Kubala L; Berglund L; Schrepfer S; Deuse T; Haddad M; Risius T; Klemm H; Reichenspurner HC; Meinertz T; Heitzer T
Circulation; 2006 Apr; 113(15):1871-8. PubMed ID: 16606792
[TBL] [Abstract][Full Text] [Related]
8. The safety of heparins in end-stage renal disease.
Sonawane S; Kasbekar N; Berns JS
Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408
[TBL] [Abstract][Full Text] [Related]
9. [Low-molecular-weight heparins versus unfractionated heparin for treatment of hemodialysed patients].
Kes P; Basić-Jukić N; Jurić I
Lijec Vjesn; 2007; 129(8-9):305-8. PubMed ID: 18198633
[No Abstract] [Full Text] [Related]
10. Effects of enoxaparin on myeloperoxidase release during hemodialysis.
Gozdzikiewicz J; Borawski J; Koc-Zorawska E; Mysliwiec M
Hemodial Int; 2014 Oct; 18(4):819-24. PubMed ID: 24837008
[TBL] [Abstract][Full Text] [Related]
11. Effects of unfractionated and fractionated heparins on myeloperoxidase activity and interactions with endothelial cells: possible effects on the pathophysiology of equine laminitis.
de la Rebière G; Franck T; Deby-Dupont G; Salciccia A; Grulke S; Péters F; Serteyn D
Vet J; 2008 Oct; 178(1):62-9. PubMed ID: 17942351
[TBL] [Abstract][Full Text] [Related]
12. Active inhibitory effect of nafamostat mesylate against the elevation of plasma myeloperoxidase during hemodialysis.
Inose K; Ono K; Tsutida A; Onai M; Komai M; Uehara K; Yano S; Naruse T
Nephron; 1997; 75(4):420-5. PubMed ID: 9127328
[TBL] [Abstract][Full Text] [Related]
13. [Heparin-induced thrombocytopenia in hemodialysis. Case report and review of the literature].
Henríquez F; Rodríguez A; Mora C; Sánchez-Deig E; Macía M; Navarro J
Nefrologia; 2006; 26(6):734-7. PubMed ID: 17227252
[TBL] [Abstract][Full Text] [Related]
14. Low-molecular-weight heparin for routine hemodialysis.
Davenport A
Hemodial Int; 2008 Oct; 12 Suppl 2():S34-7. PubMed ID: 18837768
[TBL] [Abstract][Full Text] [Related]
15. Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes.
Krieter DH; Lemke HD; Wanner C
Nephrol Dial Transplant; 2006 Feb; 21(2):546; author reply 546. PubMed ID: 16249195
[No Abstract] [Full Text] [Related]
16. [Present opinions concerning the administration of low molecular weight heparins in hemodialysis patients].
Drozdz M; Kowalczyk-Michałek M; Kraśniak A; Sułowicz W
Przegl Lek; 2005; 62(4):257-9. PubMed ID: 16229247
[TBL] [Abstract][Full Text] [Related]
17. Role of heparin and low-molecular-weight heparins in the management of acute ischemic stroke.
Padma V; Fisher M; Moonis M
Expert Rev Cardiovasc Ther; 2006 May; 4(3):405-15. PubMed ID: 16716101
[TBL] [Abstract][Full Text] [Related]
18. Heparin and low-molecular-weight heparin.
Gray E; Mulloy B; Barrowcliffe TW
Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
[TBL] [Abstract][Full Text] [Related]
19. Selection of anticoagulants for leukocytapheresis therapy in cases of active ulcerative colitis.
Kanke K; Hoshino M; Tominaga K; Nakano M; Terano A; Hiraishi H
Blood Purif; 2007; 25(4):370-6. PubMed ID: 17785966
[TBL] [Abstract][Full Text] [Related]
20. Low molecular weight heparins in patients with renal insufficiency.
Symes J
CANNT J; 2008; 18(2):55-61. PubMed ID: 18669012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
